Expression of estrogen receptors (α, β) and insulin-like growth factor-I in breast tissue from surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen

The novel estrogen receptor ERβ could be a key factor for proliferation and breast cancer risk. In a primate model for long-term HRT, surgically postmenopausal cynomolgus macaques were treated for 35 months with conjugated equine estrogens (CEE), medroxyprogesterone acetate (MPA), CEE+MPA and tamoxi...

Full description

Saved in:
Bibliographic Details
Published inBreast (Edinburgh) Vol. 11; no. 4; pp. 295 - 300
Main Authors Isaksson, E., Wang, H., Sahlin, L., von Schoultz, B., Masironi, B., von Schoultz, E., Cline, J.M.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.08.2002
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The novel estrogen receptor ERβ could be a key factor for proliferation and breast cancer risk. In a primate model for long-term HRT, surgically postmenopausal cynomolgus macaques were treated for 35 months with conjugated equine estrogens (CEE), medroxyprogesterone acetate (MPA), CEE+MPA and tamoxifen ( n = 5 in all groups). The immunohistochemical expression of ERα, ERβ and IGF-I in breast tissue was quantified by image analysis. Overall the levels of ERβ were higher than for ERα. In untreated animals, the median area of positive cells was 58% and 21%. The lowest levels for ERβ were seen during treatment with CEE/MPA (3%) and in this group the expression of ERβ was lower than for ERα. Tamoxifen had effects similar to estrogen. ERβ may have a role to modulate the proliferative response following activation of ERα. The results suggest that hormonal treatments have a different influence on the balance ERβ/ERα in breast tissue.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-9776
1532-3080
DOI:10.1054/brst.2002.0422